It is especially pleasing that the discovery of this drug was enabled by a partnership between GlaxoSmithKline and Human Genome Sciences. To me, this study shows how the genomic approach to small molecule drug discovery can lead to a potential new class of drugs for the treatment of an important disease of man. Drugs that inhibit Lp-PLA 2 may reduce the risk of atherosclerotic plaque formation and cardiovascular disease. Scientists at GlaxoSmithKline Beecham recognized the potential importance of Lp-PLA 2 for the treatment of cardiovascular disease. They sought a means to obtain large quantities of the Lp-PLA 2 enzyme.
Cardiovascular disease is a major health problem worldwide.
We are proud to have contributed to a new therapeutic approach to the control and treatment of this serious disease. I believe that this example will prove to be a classic in the use of genomics information to provide new drugs for the treatment and cure of many ills of mankind. As the trials progress on this class of compounds, our company will benefit from milestone payments related to clinical progress. Should a drug be commercialized for the prevention and treatment of cardiovascular disease, Human Genome Sciences is due significant royalties. Our company also has an option to co-promote an approved drug in the North American and European markets.